Jingfeng pharmaceutical lost 140 million in the first three quarters, down 200% year on year

On October 28, Jingfeng pharmaceutical released the third quarter quarterly report, and the overall operating revenue declined seriously, which was not optimistic Since 2019, the operating revenue has reached 1.033 billion yuan, 1.491 billion yuan in the same period of last year, a year-on-year decrease of 30.76%, which is the most noteworthy and most concerned issue of many shareholders: Jingfeng pharmaceutical has a net loss of 140 million yuan since the beginning of the year, and the stock has declined, which is not very optimistic Therefore, in the report, Jingfeng pharmaceutical has roughly estimated the total revenue in 2019 based on the above situation In 2019, it is estimated that the net profit loss will reach 400 million yuan, with a change of 260.59% The main reasons for the loss are as follows: 1 Affected by the price reduction of drug bidding and local auxiliary drug policies, the sales volume of Shenxiong glucose injection, the main product of the company, fell; indirectly affected by the "4 + 7" volume purchase, the sales unit price of some products of the company decreased, resulting in the decrease of sales revenue 2 The change of medical insurance caused by the change of product name of elemene product causes the sales revenue of the product to drop sharply year on year in the process of handling At present, the change of medical insurance has been completed 3 During the marketing reform of the company, the adjustment of sales personnel has not been completed, and the sales volume of some products fluctuates, resulting in the decrease of revenue 4 In order to expand the basic market, realize terminal sinking and increase agency sales, the company's average selling price has declined 5 The company carried out marketing reform and strengthened professional academic promotion work, resulting in the increase of overall sales promotion costs However, in the report, Jingfeng pharmaceutical did not take measures against the cause of the loss It is believed that in the current severe form, the first task of Jingfeng pharmaceutical must be to make a series of changes, which we believe we will have the opportunity to see in the 2018 annual report Penicillin statement: this opinion only represents the author, not the position of yaozhi.com, welcome to exchange and supplement in the message area; if you need to reprint, please be sure to indicate the author and source of the article.